NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer

Monika Devanaboyina; Jasskiran Kaur; Emma Whiteley; Leslie Lin; Katelyn Einloth; Susan Morand; Laura Stanbery; Danae Hamouda; John Nemunaitis

doi:10.3389/or.2022.10568

NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer

Oncol Rev. 2022 Oct 3:16:10568. doi: 10.3389/or.2022.10568. eCollection 2022.

Authors

Monika Devanaboyina¹, Jasskiran Kaur¹, Emma Whiteley¹, Leslie Lin¹, Katelyn Einloth¹, Susan Morand¹, Laura Stanbery², Danae Hamouda¹, John Nemunaitis²

Affiliations

¹ Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States.
² Gradalis, Inc., Carrollton, TX, United States.

Abstract

Immune disorders and cancer share a common pathway involving NF-κb signaling. Through involvement with GM-CSF, NF-κB can contribute to proliferation and activation of T- and B- cells as well as immune cell migration to sites of inflammation. In breast cancer, this signaling pathway has been linked to resistance with endocrine and chemotherapies. Similarly, in ovarian cancer, NF-κB influences angiogenesis and inflammation pathways. Further, BRCA1 signaling common to both breast and ovarian cancer also has the capability to induce NF-κB activity. Immunotherapy involving NF-κB can also be implemented to combat chemoresistance. The complex signaling pathways of NF-κB can be harnessed for developing cancer therapeutics to promote immunotherapy for improving patient outcomes.

Keywords: NFκB; breast cancer; immunotherapy; inflammatory signaling; ovarian cancer; tumor signaling.

Publication types

Review